Literature DB >> 1942253

Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation.

B A Sullenger1, H F Gallardo, G E Ungers, E Gilboa.   

Abstract

Overexpression of trans-acting response element (TAR)-containing sequences (TAR decoys) in CEM SS cells renders cells resistant to human immunodeficiency type 1 (HIV-1) replication. Mutagenesis of TAR was used to investigate the molecular mechanism underlying the observed inhibition. A nucleotide change which disrupts the stem structure of TAR or sequence alterations in the loop abolish the ability of the corresponding TAR decoy RNAs to inhibit HIV replication. A compensatory mutation which restores the stem structure also restores TAR decoy RNA function. Synthesis of viral RNA is drastically reduced in cells expressing a functional TAR decoy RNA, but it is unaffected in cells expressing a mutant form of TAR decoy RNA. It is therefore concluded that overexpression of TAR-containing sequences in CEM SS cells interferes with the process of Tat-mediated transactivation of viral gene expression. However, the phenotype of several mutations suggests that TAR decoy RNA does not inhibit HIV-1 gene expression by simply sequestering Tat but rather does so by sequestering a transactivation protein complex, implying that transactivation requires the cooperative binding of both Tat and a loop-binding cellular factor(s) to TAR. Expression of wild-type or mutant forms of TAR had no discernible effects on cell viability, thus reducing concerns about using TAR decoy RNAs as part of an intracellular immunization protocol for the treatment of AIDS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942253      PMCID: PMC250772     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

Authors:  B A Sullenger; H F Gallardo; G E Ungers; E Gilboa
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

Review 2.  The HIV-1 Tat protein: an RNA sequence-specific processivity factor?

Authors:  B R Cullen
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro.

Authors:  M G Cordingley; R L LaFemina; P L Callahan; J H Condra; V V Sardana; D J Graham; T M Nguyen; K LeGrow; L Gotlib; A J Schlabach
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 4.  Tat and Rev: positive regulators of HIV gene expression.

Authors:  C A Rosen; G N Pavlakis
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

5.  Fragments of the HIV-1 Tat protein specifically bind TAR RNA.

Authors:  K M Weeks; C Ampe; S C Schultz; T A Steitz; D M Crothers
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

6.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.

Authors:  S Roy; U Delling; C H Chen; C A Rosen; N Sonenberg
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

7.  Co-existence of vinculin and a vinculin-like protein of higher molecular weight in smooth muscle.

Authors:  J R Feramisco; J E Smart; K Burridge; D M Helfman; G P Thomas
Journal:  J Biol Chem       Date:  1982-09-25       Impact factor: 5.157

8.  Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.

Authors:  B A Sullenger; T C Lee; C A Smith; G E Ungers; E Gilboa
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

9.  TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter.

Authors:  B Berkhout; A Gatignol; A B Rabson; K T Jeang
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  37 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR.

Authors:  A V Filikov; V Mohan; T A Vickers; R H Griffey; P D Cook; R A Abagyan; T L James
Journal:  J Comput Aided Mol Des       Date:  2000-08       Impact factor: 3.686

Review 3.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

4.  A nucleolar TAR decoy inhibitor of HIV-1 replication.

Authors:  Alessandro Michienzi; Shirley Li; John A Zaia; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-10       Impact factor: 11.205

Review 5.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

Review 6.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro.

Authors:  Y F Melekhovets; S Joshi
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

8.  TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation.

Authors:  P R Bohjanen; Y Liu; M A Garcia-Blanco
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

9.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

10.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.